Abstract:Interferon-alpha (IFN-alpha) is currently the preferred antiviral treatment for children with chronic hepatitis B (CHB) aged >1-year-old. However, the evidence regarding the exact efficacy and safety in the real world is not sufficient. This study aimed to investigate the efficacy of IFN-alpha therapy in children with CHB and to provide a theoretical basis for practically identifying ideal antiviral therapies for CHB children. Clinical manifestations, baseline characteristics, related laboratory tests, and adverse events were retrospectively analyzed in children with CHB who visited the Children's Hospital of Fudan University, were treated with IFN-alpha and were followed up from January 2003 to October 2018. A total of 18 immune-active patients without advanced fibrosis were enrolled, and their average age at the start of treatment was 4.45 +/- 2.75 years old. IFN alpha-2b was administered subcutaneously by body surface area (BSA) category, based on 3MU/m(2), for a median 48 weeks. Before treatment, the alanine aminotransferase (ALT) range was 81 to 409U/L (median 158U/L). The median hepatitis B virus (HBV)-DNA load was 9.89 x 10(7) IU/mL, and the HBV-DNA load varied from 3.10 x 10(4) to 4.56 x 10(8) IU/mL. The ALT levels of 17 children became normal at an average of 12 weeks during treatment, and those of 1 child became normal at 6 weeks after IFN-alpha withdrawal. Sixteen (88.9%, 16/18) children became HBV-DNA negative (<10(3) IU/mL) at an average of 24 weeks during treatment, while 1 became negative at 96 weeks after IFN-alpha withdrawal and 1 remained HBV-DNA positive. HBV e antigen (HBeAg) seroconversion occurred in 13 of 14 (92.9%, 13/14) HBeAg-positive patients at an average of 12 weeks during treatment. HBV s antigen (HBsAg) loss or seroconversion occurred in 4 (22.2%, 4/18) patients at an average of 21 weeks during treatment. Only mild flu-like symptoms and transient neutropenia appeared in some children at the early treatment stage. No severe abnormal results were observed in other laboratory parameters. The antiviral monotherapy of 48 weeks of IFN-alpha was well tolerated and good responded, which was associated with higher rates of HBeAg seroconversion and HBsAg clearance in the children in this study than in previously reported adults and pediatric patients.

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Interferon Alpha-2B with and Without Ribavirin in the Treatment of Hepatitis B E Antigen-Positive Chronic Hepatitis B: a Randomized Study.

The clinical analysis of PEG-interferon alpha-2b therapy in 61 cases of HBeAg-positive chronic hepatitis B

[A Clinical Study of the Efficacy and Safety of Secretory Human Interferon Alpha-2A Treatment for Chronic Hepatitis B].

[Serum HBV-DNA Level Can Predict Treatment Effectiveness in Patients with Chronic Hepatitis B Using Interferon-Alpha-2a].

Relationship Between the Antiviral Effect and Changes in Helper T (th) Cytokine Levels in the Treatment of Chronic Hepatitis B Using Lamivudine Combined with Alpha Interferon

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.

[Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].

Interferon therapy of chronic hepatitis B

Efficacy and response prediction in the treatment of HBeAg-positive chronic hepatitis B with interferon alpha-2b

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B.

Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B

Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan

Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China.

[Effect of Interferon-Alpha Therapy on the Capacity of Antigen Presenting of Peripheral Blood Dendritic Cells from Patients with Chronic Hepatitis B].

Effect of interferon therapy on quality of life in patients with chronic hepatitis B

Effects of Antiviral Effects of Agents and Prognosis of Chronic Hepatitis B

[Factors Associated with HBeAg Seroconversion in Chronic Hepatitis B Patients Treated with Interferon Alfa-2A].